Comparing ML models in small molecule drug discovery (fbdd-lit.blogspot.com)

Recent discussions surrounding the study "A2025: Practically Significant Method Comparison Protocols for Machine Learning in Small Molecule Drug Discovery" have highlighted crucial considerations for the application of machine learning (ML) to drug discovery. The authors advocate that the credibility of the field would benefit from stricter guidelines on terminologies like "outperform" in scientific publications. Significant concerns were raised about the need for ML modellers to properly account for the adjustable parameters and data clustering during cross-validation, as oversights in these areas can lead to overly optimistic evaluations of model performance. These guidelines are poised to elevate the standards of ML benchmarking, ensuring that drug discovery processes are not only more robust but also impactful. This study is particularly significant for the AI/ML community as it challenges the conventional reliance on hyperbolic assertions of model efficacy, urging a shift towards more hypothesis-driven approaches in drug design. It argues that while ML models can predict compound behaviors, understanding the nuances of biological interactions and employing sound experimental processes remain crucial for success in the field. Key technical discussions include the limitations of in vitro assays for modeling drug behavior and the necessity of comprehensively understanding quantitative limits in assay design to improve the reliability of ML predictions. These insights will shape future research methodologies, potentially redefining how ML models are constructed and validated within pharmaceutical contexts.